List view / Grid view
New data shows Lilly’s Olumiant (baricitinib) significantly reduces the risk of death in hospitalised COVID-19 patients receiving invasive mechanical ventilation or ECMO.
Eli Lilly has given an update on its neutralising antibody programmes, including its combination therapy in patients with COVID-19.
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
Eli Lilly has announced it is to acquire Dermira for $18.75 per share, or approximately $1.1 billion, which will expand Lilly's immunology pipeline.
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
Olaratumab is the first monoclonal antibody, in combination with doxorubicin, to be recommended for the treatment of advanced soft tissue sarcoma.
23 August 2016 | By AstraZeneca
AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.
13 July 2016 | By Victoria White, Digital Content Producer
Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer...
14 June 2016 | By Victoria White, Digital Content Producer
Jardiance reduced the risk for new-onset or worsening kidney disease by 39% versus placebo in adults with type 2 diabetes with established CV disease...
13 June 2016 | By Victoria White, Digital Content Producer
New data for Jardiance (empagliflozin) show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes...
Lilly has announced new findings from separate studies of Trulicity (dulaglutide) and Tradjenta (linagliptin) at the American Diabetes Association 76th Scientific Sessions.
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
6 June 2016 | By Victoria White, Digital Content Producer
Data were presented from two early-phase trials evaluating Lilly's Alimta and Cyramza in combination with Merck's Keytruda in patients with NSCLC...
11 May 2016 | By Victoria White, Digital Content Producer
Lilly’s psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its high clinical efficacy and good safety profile, according to an analyst with research and consulting firm GlobalData.
